This is a Phase 3, multi-center, open-label study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
Eligible subjects will have previously completed the SOL-BED-301 (ENGAGE) study. This study consists of a Baseline Visit, a 2-week Titration Phase, and a 50-week Maintenance Phase, followed by a 1-week follow-up period.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
300
Taken once daily.
Long-term Safety
Incidence of treatment-emergent adverse events following dosing with solriamfetol
Time frame: Up to 52 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Research Site
Encino, California, United States
Clinical Research Site
Long Beach, California, United States
Clinical Research Site
Santa Ana, California, United States
Clinical Research Site
Walnut Creek, California, United States
Clinical Research Site
West Covina, California, United States
Clinical Research Site
Cromwell, Connecticut, United States
Clinical Research Site
Fort Myers, Florida, United States
Clinical Research Site
Hialeah, Florida, United States
Clinical Research Site
Jacksonville, Florida, United States
Clinical Research Site
Lauderhill, Florida, United States
...and 21 more locations